cabo-nivo or cabo-nivo-ipi for metastatic genitourinary tumors
Published 3 years ago • 101 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
4:01
cosmic-313: cabo nivo ipi in 1l advanced rcc of imdc intermediate or poor risk
-
2:38
checkmate 9er: cabo-nivo superior to sunitinib in extended follow-up results
-
1:26
neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccrcc
-
3:28
checkmate 920: nivo plus ipi for advanced rcc with brain metastases
-
3:31
cabozantinib–nivolumab and ipilimumab combinations show potential for gu cancers | andrea apolo
-
8:48
nivo ipi in rcc: omnivore
-
2:40
combining agents to improve response rates in genitourinary cancer
-
1:49
cosmic-313: cabozantinib with nivolumab and ipilimumab in untreated arcc
-
2:34
nivo cabozantinib vs sunitinib for first-line treatment of arcc
-
2:40
updates on the cabopre phase ii trial in patients with metastatic renal cell carcinoma
-
1:20
promising results of cabozantinib plus nivolumab in non-clear cell rcc
-
0:44
unmet needs in bladder cancer in the immunotherapy era
-
0:29
dr. mckay on fda approval of frontline cabozantinib in rcc
-
5:47
immunotherapy for metastatic kidney cancer shows increased survival
-
0:56
dr. apolo on immunotherapy combinations with cabozantinib in genitourinary tumors
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
2:56
#esmo22 highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. rcc: cosmic-313
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
4:45
highlights in kidney and bladder cancer at asco gu 2021